Search Medical Condition
Please enter condition
Please choose location from dropdown

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

Found (55033) clinical trials

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.  

Phase

Qualified participants will receive: Study-related medication at no cost Study-related medical exams at no cost Compensation for time and travel Insurance is not needed to participate in this study.  

Phase N/A

Qualified participants will receive: Study-related medication at no cost Study-related medical exams at no cost Compensation for time and travel  Insurance is not needed to participate in this study.  

Phase N/A

Qualified participants will receive: Study-related medication at no cost Study-related medical exams at no cost Compensation for time and travel  

Phase N/A

Qualified participants will receive: Study-related medication at no cost Study-related medical exams at no cost Compensation for time and travel

Phase N/A

Qualified participants will receive: Study-related medication at no cost Study-related medical exams at no cost Compensation for time and travel

Phase N/A

People who may develop Alzheimer's Disease are asked to participate in a research study being conducted by New York University School of Medicine.

Phase N/A

The study is designed to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19.  The investigational medication is called CD24Fc. Participants will be randomly assigned to one of two treatment "arms" for the study and neither the participant, nor the study team will …

Phase

DURATION: Subjects who meet the inclusion and exclusion criteria will be enrolled into the study for up to 96 weeks. Enrolled subjects will receive BCX7353 150 mg administered orally once daily (QD). A total of 8 visits will occur over the course of the subject’s participation in this study. Study …

Phase